Uganda's Health Ministry investigates fake drugs

20 May 2007

Uganda's Ministry of Health and National Drug Authority have launched an investigation into the spread of fake malaria drugs in the country, according to the Kaiser Family Foundation's Global Health Reporting.org newsletter. A combination of quinine and sulfate, marketed under the brand name QuineA, has been linked to a series of adverse events involving children being injected with the drug.

However, the NDA has admitted that it cannot confirm that local reports of children suffering alleged side effects from QuineA are related to reports of counterfeiting. The agency's Commissioner for Community Health told the Uganda-based Monitor newspaper: "we are investigating, if there is anything wrong, the law will take its course."

Uganda's Minister of State for Health, Emmanuel Otaala, said that the government would alert the public to the continuing threat of fake drugs. He said that a particular concern is that fake or adulterated products would increase the spread of drug-resistant malaria.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight